• Daré Bioscience shareholders approved potential future common stock issuance upon exercise of outstanding warrants at a November 10, 2026 special meeting.
• Shareholders also authorized adjournment to solicit additional proxies supporting the issuance, but sufficient votes made adjournment unnecessary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051235), on November 12, 2026, and is solely responsible for the information contained therein.